Risk Factors for Disseminated Histoplasmosis in a Cohort of HIV-Infected Patients in French Guiana

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 7-

  Nacher, Mathieu ^a,b,c   Adenis, Antoine ^a   Blanchet, Denis ^c,d   Vantilcke, Vincent ^e   Demar, Magalie ^a,c   Basurko, Célia ^a   Gaubert Maréchal, Emilie ^b   Dufour, Julie ^f   Aznar, Christine ^c,d   Carme, Bernard ^c,d   Couppié, Pierre ^c,f  

^a CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^b CH de Cayenne   (French Guiana)

^c UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^d EA 3593   (French Guiana)

^e Centre Hospitalier de l'Ouest Guyanais   (French Guiana)

^f Service Dermatologie   (French Guiana)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; FLUCONAZOLE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRENCH GUIANA; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PNEUMOCYSTOSIS; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT; ADOLESCENT; AGED; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SURVIVAL;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; FRENCH GUIANA; HISTOPLASMOSIS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84893742777     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002638     Document Type: Article

References (23)

1. Colombo AL, Tobon A, Restrepo A, Queiroz-Telles F, Nucci M, (2011) Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol 49: 785-798.
2. Guimaraes AJ, Nosanchuk JD, Zancope-Oliveira RM, (2006) Diagnosis of Histoplasmosis. Braz J Microbiol 37: 1-13.
3. McKinsey DS, Spiegel RA, Hutwagner L, Stanford J, Driks MR, et al. (1997) Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 24: 1195-1203.
4. Wheat LJ, Connolly-Stringfield P, Kohler RB, Frame PT, Gupta MR, (1989) Histoplasma capsulatum polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 87: 396-400.
5. Couppie P, Aznar C, Carme B, Nacher M, (2006) American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 19: 443-449.
6. Hajjeh RA, Pappas PG, Henderson H, Lancaster D, Bamberger DM, et al. (2001) Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 32: 1215-1220.
7. Nacher M, Adenis A, Adriouch L, Dufour J, Papot E, et al. What is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. Am J Trop Med Hyg 84: 239-240.
8. Nacher M, Aznar C, Blanchet D, Demar M, El Guedj M, et al. (2006) AIDS-related disseminated histoplasmosis in the greater Caribbean: how frequent is it? AIDS 20: 951-952.
9. Nacher M, Sarazin F, El Guedj M, Vaz T, Alvarez F, et al. (2006) Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J Acquir Immune Defic Syndr 41: 468-470.
10. Manos NE, Ferebee SH, Kerschbaum WF, (1956) Geographic variation in the prevalence of histoplasmin sensitivity. Dis Chest 29: 649-668.
11. Floch H, (1953) [Histoplasmosis Darling in research in French Guiana]. Bull Soc Pathol Exot Filiales 46: 288-290.
12. Hay RJ, White HS, Fields PE, Quamina DB, Dan M, et al. (1981) Histoplasmosis in the eastern Caribbean: a preliminary survey of the incidence of the infection. J Trop Med Hyg 84: 9-12.
13. Nacher M, Huber F, El Guedj M, Vaz T, Magnien C, et al. (2007) Risk factors for death among patients in French Guiana: 1996-2005. HIV Med 8: 472-474.
14. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, et al. (2008) Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 168: 532-540.
15. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, et al. (1999) Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study. Ann Intern Med 130: 570-577.
16. Schnizlein-Bick C, Durkin M, Kohler S, Connolly P, LeMonte A, et al. (2003) Effects of CD4 and CD8 T lymphocyte depletion on the course of histoplasmosis following pulmonary challenge. Med Mycol 41: 189-197.
17. Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr, Klein BS, (2003) Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 197: 1405-1416.
18. Anderson RE, Shiboski SC, Royce R, Jewell NP, Lang W, et al. (1991) CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations. AIDS 5: 213-215.
19. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, (1995) CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 95: 2061-2066.
20. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, et al. (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16: 83-92.
21. Nightingale SD, Cal SX, Peterson DM, Loss SD, Gamble BA, et al. (1992) Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 6: 191-194.
22. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, et al. (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 332: 700-705.
23. Couppie P, Sobesky M, Aznar C, Bichat S, Clyti E, et al. (2004) Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 38: 134-138.